Last $39.34 USD
Change Today -1.52 / -3.72%
Volume 560.9K
CMRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:20 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

chimerix inc (CMRX) Snapshot

Open
$41.23
Previous Close
$40.86
Day High
$41.89
Day Low
$38.91
52 Week High
12/22/14 - $41.89
52 Week Low
05/20/14 - $14.02
Market Cap
1.6B
Average Volume 10 Days
548.0K
EPS TTM
$-1.56
Shares Outstanding
40.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHIMERIX INC (CMRX)

chimerix inc (CMRX) Related Businessweek News

View More BusinessWeek News

chimerix inc (CMRX) Details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

67 Employees
Last Reported Date: 11/7/14
Founded in 2000

chimerix inc (CMRX) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $340.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $275.0K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2013.

chimerix inc (CMRX) Key Developments

Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157

Chimerix, Inc. and ContraVir Pharmaceuticals, Inc. announced that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. CMX157 is a highly potent analog of the successful antiviral drug tenofovir DF (Viread). Under the agreement, ContraVir licenses CMX157 from Chimerix in exchange for an upfront payment consisting of 120,000 shares of ContraVir preferred stock with a stated value of $1.2 million. In addition, Chimerix is eligible to receive up to approximately $20 million in clinical, regulatory and initial commercial milestones in the United States and Europe, as well as royalties and additional milestones based on commercial sales in those territories.

Chimerix, Inc. Appoints Ronald C. Renaud, Jr. to its Board of Directors

Chimerix, Inc. announced Ronald C. Renaud, Jr. has been appointed to its Board of Directors. Mr. Renaud currently serves as Chief Executive Officer at RaNA Therapeutics. Prior to Mr. Renaud's appointment as Chief Executive Officer at RaNA Therapeutics in December 2014, he served as President and Chief Executive Officer at Idenix Pharmaceuticals since October 2010.

Chimerix, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:30 PM

Chimerix, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMRX:US $39.34 USD -1.52

CMRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr198.00 DKK +6.00
Bioporto A/S kr1.84 DKK -0.03
Emergent Biosolutions Inc $26.83 USD -0.22
GlaxoSmithKline PLC 1,390 GBp -2.00
Novartis AG SFr.93.55 CHF +0.50
View Industry Companies
 

Industry Analysis

CMRX

Industry Average

Valuation CMRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 389.2x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 378.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIMERIX INC, please visit www.chimerix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.